VJHemOnc is committed to improving our service to you

ICML 2019 | Zanubrutinib plus obinutuzumab: CLL, SLL & FL

VJHemOnc is committed to improving our service to you

Constantine Tam

Constantine Tam, MD, FRACP, FRCPA, Peter MacCallum Cancer Centre, Melbourne, Australia, discusses the use of zanubrutinib plus obinutuzumab in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and relapsed/refractory follicular lymphoma. This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter